MENLO PARK, Calif.,
April 20, 2017 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, announced the last subject visit in its Phase 2b trial was
on March 24, 2017 and the last
investigational site close-out visit was April 7, 2017. Based on the timing of the
study completion, the company now plans to announce topline
data from the trial in the first half of May.
The Phase 2b study was a dose-finding clinical trial to assess
the efficacy and safety of BPX-01 for the treatment of acne
vulgaris. The 12-week, multi-center, randomized,
double-blind, three-arm, vehicle-controlled study involves 225
individuals, aged 9 to 40, who have moderate-to-severe
inflammatory, non-nodular acne vulgaris.
BPX-01[1] is a hydrophilic (non-oil-based) topical gel with
fully solubilized minocycline that can penetrate the skin to
deliver the antibiotic to where acne develops in the pilosebaceous
unit.
The company expects to present complete data from the trial to
the medical community at Alabama Dermatology Society's Dermatology
Summer Symposium, June 22-25, in
Sandestin, Fla.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based
specialty pharmaceutical company that seeks to provide products
through proprietary platform technologies for prescription,
over-the-counter and supplement applications in dermatology and
women's health. To learn more about BioPharmX, visit
www.BioPharmX.com.
Forward-Looking Statement
The information in this press release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the "safe harbor" created by those sections. This press release
contains forward-looking statements about the company's
expectations, plans, intentions and strategies, including, but not
limited to, statements regarding, the safety and medical effects of
BPX-01, the effect BPX-01 may have on the treatment of acne, the
timing of reporting and presenting trial results, commencement and
results of future tests involving BPX-01, continued and consistent
results in future tests of BPX-01 and absence of side effects of
future use of BPX-01. These forward-looking statements may be
identified by words such as "may", "plan", "expect," "anticipate,"
"believe," or similar expressions that are intended to identify
such forward-looking statements. These forward-looking statements
involve risks and uncertainties, as well as assumptions, which, if
they do not fully materialize or prove incorrect, could cause our
results to differ materially from those expressed or implied by
such forward-looking statements. The risks and uncertainties
include those described in the company's filings with the
Securities and Exchange Commission. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements. The forward-looking statements
included in this news release are made only as of the date hereof
and the company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
[1] Caution: BPX-01 is a new drug
limited by federal or U.S. law to investigational use.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-completes-last-subject-visit-in-its-phase-2b-trial-of-bpx-01-expects-to-report-topline-results-first-half-of-may-2017-300442492.html
SOURCE BioPharmX Corporation